Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R03 Clinical Trial Optional) | PAR 18 527

Opportunity Information: Apply for PAR 18 527

The grant opportunity titled "Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R03 Clinical Trial Optional)" (Funding Opportunity Number PAR-18-527) is a National Institutes of Health (NIH) discretionary grant designed to support smaller, focused research projects that improve what is known about synthetic psychoactive drugs. The central goal is to deepen scientific and clinical understanding of how these substances are used, how they work in the body and brain, what short- and long-term health harms they cause, and what practical approaches can prevent use and reduce harm, including both emergency department responses and longer-range treatment strategies. Because the mechanism is an R03, it is generally aligned with short-duration, limited-budget studies that can generate early evidence, fill key gaps, and lay groundwork for larger future projects. The FOA is labeled "Clinical Trial Optional," meaning applicants can propose studies that do or do not include a clinical trial component, depending on what best fits the research question.

The research scope emphasized by the announcement is broad but clearly centered on real-world impact. Projects may examine patterns of use and exposure, including how emerging synthetic drugs enter communities and how people obtain and consume them. A major focus is on mechanisms of action, which can include studying receptor interactions, neurobiological pathways, toxicology, or other pharmacologic mechanisms that explain why a given synthetic compound produces psychoactive effects and why it may cause severe or unexpected medical complications. The FOA also highlights health effects, which can range from acute toxicity (for example, presentations that drive emergency department visits) to longer-term consequences that affect mental health, cognition, or physical systems. On the applied side, the opportunity explicitly calls for prevention strategies as well as approaches to treat patients in emergency departments and to support long-range treatment, reflecting an interest in the full continuum from prevention and early identification to acute care and ongoing recovery-oriented interventions.

From an administrative standpoint, the award is a grant in the education and health activity category and is associated with CFDA number 93.279. The listed award ceiling is $50,000, indicating that budgets are expected to be modest and targeted, consistent with the R03 mechanism. The opportunity was created on December 18, 2017, and the original closing date shown is May 7, 2020, which indicates the timeline provided in the source data (applicants would still need to verify whether the announcement has subsequent due dates, has been reissued, or has expired in current NIH systems).

Eligibility is expansive and intentionally inclusive, allowing many types of organizations to apply. Eligible applicants include state, county, city or township governments, and special district governments, along with independent school districts. Higher education institutions are eligible across categories, including public and state-controlled institutions of higher education as well as private institutions of higher education. Tribal entities are eligible, including federally recognized Native American tribal governments and Native American tribal organizations other than federally recognized tribal governments, and the FOA also explicitly calls out Indian/Native American Tribal Governments (other than federally recognized), Tribally Controlled Colleges and Universities (TCCUs), and U.S. territories or possessions. Nonprofits can apply whether or not they have 501(c)(3) status, as long as they are not institutions of higher education in those specific nonprofit categories. For-profit organizations are eligible (other than small businesses), and small businesses are also eligible, along with an "Others" category that NIH often uses to capture additional allowable applicant types.

The announcement also highlights additional eligible applicant groups to encourage participation from organizations that serve historically underrepresented or underserved communities and from a wide range of institutional settings. These include Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, and Historically Black Colleges and Universities (HBCUs). It also includes faith-based or community-based organizations, eligible agencies of the federal government, regional organizations, and non-domestic (non-U.S.) entities (foreign organizations). Taken together, that eligibility language signals NIH interest in supporting research that can be informed by diverse populations, varied clinical and community environments, and international perspectives where relevant to synthetic drug trends and harms.

Overall, this FOA supports practical, tightly scoped research aimed at reducing the harms associated with synthetic psychoactive drugs. Competitive projects under this announcement would typically be expected to identify a specific gap (for example, limited knowledge about an emerging compound's toxicity profile, a lack of evidence-based ED management approaches for certain presentations, or an unmet need for prevention messaging tailored to specific populations), propose a feasible study that can be completed within an R03-scale budget, and produce findings that can directly inform clinical practice, public health prevention, or the design of larger, more definitive studies.

• The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R03 Clinical Trial Optional)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279.
• This funding opportunity was created on 2017-12-18.
• Applicants must submit their applications by 2020-05-07. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $50,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for PAR 18 527

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: